Breaking News

Boyds Join Clinical Program Team to Develop Orphan Drug

Clinical research specialists Accenture, Aptus, Boyds and KJC bring strong experience to CTDs orphan drug program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boyds has joined CTD Holdings’ International Clinical Program Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol Cyclo with Accenture. CTD Holdings, Inc. is a family of biotechnology companies that develop cyclodextrin-based treatments and other products. Trappsol Cyclo is used for the treatment of Niemann-Pick Type C, a rare and often fatal genetic disease that occurs primarily in young children. The company holds orphan designation for Trappsol Cyclo in Eur...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters